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SEMINAL CONTRIBUTIONSLong-term treatment of uterine
fibroids with ulipristal acetate*
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Philippe Bouchard, M.D.,e Bart C. J. M. Fauser, M.D.,f David H. Barlow, F.R.C.O.G.,g Santiago Palacios, M.D.,h
Olivier Donnez, M.D.,i Elke Bestel, M.D.,j Ian Osterloh, M.R.C.P.,k and Ernest Loumaye, M.D.,l for the PEARL III
and PEARL III Extension Study Group
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Glasgow, Scotland; h Palacios' Institute of Women's Health, Madrid, Spain; i Centre Hospitalier Universitaire Universite
Catholique de Louvain Mont-Godinne Dinant, Yvoir, Belgium; j PregLem S.A., Geneva, Switzerland; k OsterMed Ltd.,
Birmingham, United Kingdom; and l ObsEva S.A. Geneva, SwitzerlandObjective: To investigate the efficacy and safety of ulipristal acetate (UPA) for long-term treatment of symptomatic uterine fibroids.
Design: Repeated intermittent open-label UPA courses, each followed by randomized double-blind norethisterone acetate (NETA) or
placebo.
Setting: European clinical gynecology centers.
Patient(s): Two hundred and nine women with symptomatic fibroids including heavy menstrual bleeding.
Intervention(s): Patients received up to four 3-month courses of UPA 10 mg daily, immediately followed by 10-day double-blind
treatment with NETA (10 mg daily) or placebo.
Main Outcome Measure(s): Amenorrhea, fibroid volume, endometrial histology.
Result(s): After the first UPA course, amenorrhea occurred in 79% of women, with median onset (from treatment start) of 4 days (in-
terquartile range, 2–6 days). Median fibroid volume change was 45% (interquartile range, 66%; 25%). Amenorrhea rates were
89%, 88%, and 90% for the 131, 119, and 107 women who received treatment courses 2, 3, and 4, respectively. Median times to amen-
orrhea were 2, 3, and 3 days for treatment courses 2, 3, and 4, respectively. Median fibroid volume changes from baseline were 63%,Received January 22, 2014; revised and accepted February 6, 2014; published online March 12, 2014.
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SEMINAL CONTRIBUTION67%, and 72% after treatment courses 2, 3, and 4, respectively. All endometrial biopsies showed benign histology without hyper-
plasia; NETA did not affect fibroid volume or endometrial histology.
Conclusion(s): Repeated 3-month UPA courses effectively control bleeding and shrink
fibroids in patients with symptomatic fibroids.
Clinical trial registration: ClinicalTrials.gov (www.clinicaltrials.gov) registration numbers
NCT01156857 (PEARL III) and NCT01252069 (PEARL III extension). (Fertil Steril 2014;
101:1565–73. 2014 by American Society for Reproductive Medicine.)
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scanner” in your smartphone’s app store or app marketplace.L eiomyomas or fibroids are benign hormone-sensitivetumors of uterine smooth-muscle cells, frequentlyinvolving point mutations and/or complex chromo-
somal rearrangements (1). They occur in about 20%–40% of
women of reproductive age (2). Heavy menstrual bleeding
(HMB), pelvic pressure and pain, and reproductive dysfunc-
tion are common symptoms that impair women's health
and quality of life (QoL) (3, 4). Surgical interventions,
especially hysterectomy, still predominate the treatment
strategy (5). Options for medical therapy are currently
limited to preoperative reduction of symptoms related to
uterine bleeding and fibroid size; GnRH agonists are
licensed but only for short-term therapy owing to safety con-
cerns (loss of bone mass) and adverse reactions (hot flashes)
(6, 7). The levonorgestrel-releasing intrauterine device, while
not approved for this indication, has been found to reduce
menstrual blood loss in women with uterine fibroids, but its
efficacy is reduced in patients with a distorted uterus (8). Since
February 2012, ulipristal acetate (UPA) is also approved in Eu-
rope for preoperative fibroid treatment (9). For the many
women wishing to avoid surgery, there remains a substantial
need for effective long-term medical therapy.
UPA is a selective P receptor modulator (SPRM) that
potently modulates P-receptor activity (10) with proapopto-
tic/antiproliferative effects onfibroid cells (11) and with phar-
macokinetic properties supporting once daily dosing (12).
Two short-term (3 months) randomized clinical trials showed
that UPA effectively controls HMB and shrinks fibroids (13,
14). After treatment cessation, menstruation usually returns
within 4–5 weeks, but fibroid volume reduction can be
sustained for up to 6 months. In addition, treatment with
UPA reduced fibroid-associated pain, improved QoL, and re-
vealed no safety concerns (13, 14). Clinical trials have also
shown that SPRM administration can lead to a pattern of
benign, nonphysiological, nonproliferative, histological
features of the endometrium termed P receptor modulator
associated endometrial changes (PAEC) (15–17). These
changes spontaneously reverse over a few weeks to months
after cessation of the 3-month UPA treatment (13, 14, 18).
Hence, intermittent courses of 3-month UPA treatment with
off-treatment intervals are a potential option for the long-
term medical management of fibroids (9).
In these two studies, the PGL4001 (UPA) Efficacy Assess-
ment in Reduction of Symptoms due to Uterine Leiomyomata
(PEARL) III trial and its extension, we evaluated the sustained1566effects of UPA on menstrual bleeding, fibroid volume, pain,
QoL, and safety during one to four 3-month UPA treatment
courses.
Owing to the long-term treatment, no suitable active
comparator to UPA was available. However, since UPA exerts
mainly antiprogestagenic effects on the endometrium, we
randomized women to receive 10 days of treatment with the
progestin norethisterone acetate (NETA) or placebo (adminis-
tered immediately after each completed UPA treatment) to
explore any effect on the reversibility of PAEC or timing
and magnitude of the next menstruation off treatment. The
off-treatment period between each UPA course included one
menstrual bleed and the beginning of a second bleed.
MATERIALS AND METHODS
Study Design and Oversight
PEARL III and its extension were long-term, open-label,
phase III trials of UPA, which were double-blinded and pla-
cebo-controlled toward the administration of progestin after
the end of each UPA treatment course. PEARL III was con-
ducted at 21 investigation centers in four countries from
July 2010 through November 2011, with 18 centers also
participating in the extension protocol until January 2013.
The trial and extension were approved by the independent
ethics committee of each participating site and were conduct-
ed in accordance with the International Conference on Har-
monisation Good Clinical Practice guidelines.Study Population
PEARL III enrolled premenopausal women with at least one
fibroidR3 cm indiameter andnone>10 cm,HMB, anduterine
size <16 weeks of gestation who were eligible for fibroid sur-
gery. Eligible women were aged 18–48 years, with body mass
index 18–40 (kg/m2) and regular menstrual cycles of 22–
35 dayswith FSH%20 IU/L.Written informed consentwas ob-
tained from all women. Themain exclusion criteria are listed in
Supplemental Table 1, available at www.fertstert.org.Randomization and Intervention
Women received a 3-month open-label course of UPA (10mg)
once daily immediately followed by double-blind oral NETA
(10 mg) once daily or matching placebo for 10 days allocated
randomly in a 1:1 ratio.VOL. 101 NO. 6 / JUNE 2014
Fertility and Sterility®UPA was started during the first 4 days of menstruation.
After the first UPA (and NETA/placebo) treatment course and
the return of menstruation, women could either leave the
study and attend a final follow-up visit 12 weeks later (PEARL
III) or, if they wished to be assessed for a further 18 months,
enroll in the PEARL III extension study to obtain up to three
further courses of UPA (and NETA/placebo), each separated
by an off-treatment period including a full menstrual cycle
up to the start of the second menstruation. Follow-up visits
in the extension study were conducted approximately
3 months after the final treatment course. The sequence of
treatments is illustrated in Supplemental Figure 1.Efficacy endpoints
We evaluated efficacy and safety endpoints after the first
treatment course (PEARL III), after each of up to three more
treatment courses (PEARL III extension), and approximately
3 months after completion of the final treatment course.
The primary efficacy endpoint was the occurrence of amenor-
rhea at the end of each UPA course. In accordance with pre-
viously published data, amenorrhea was defined as no
bleeding for a continuous period of at least 35 days (1 day
of spotting was allowed within any 35-day interval) to accu-
rately describe the degree of bleeding control during UPA
treatment under the conditions of this study (13, 14). This
differs from the general definition of amenorrhea, which is
three menstrual cycle lengths of no bleeding. Bleeding was
assessed using a semiquantitative bleeding scale. For an
exploratory endpoint, the Pictorial Blood-Loss Assessment
Chart (PBAC) (19) was used to assess the magnitude of men-
strual bleeding over 8 days at baseline (start of the first treat-
ment course) and for the first menstruation after the end of
each treatment course. A score greater than 100 indicates
HMB.
Secondary efficacy endpoints included the reduction of
the three largest fibroids identified at screening on the basis
of ultrasound performed at each center. Further secondary
endpoints were pain, measured with the Short-Form McGill
Pain questionnaire (20) and QoL, measured by the general
EQ-5D questionnaire (21) and by the specific Uterine Fibroid
Symptom and Health-Related Quality of Life (UFS-QoL) ques-
tionnaire (22). Additional details are presented in the
Supplemental Material.Assessment of Safety Endpoints
Safety endpoints included the number and proportion of
women experiencing treatment-emergent adverse events
(TEAEs), including clinically significant changes in vital
signs, physical examination, gynecological and/or breast ex-
amination, electrocardiogram (ECG), ovarian ultrasound,
changes from baseline in endometrial thickness, and clini-
cally significant changes in endometrial biopsy. The fre-
quency and severity of adverse events (spontaneously
reported or elicited by the investigators with the use of non-
leading questions) were recorded on standard forms at every
visit. Serious adverse events were recorded up to the last visit
approximately 3 months after treatment cessation. OtherVOL. 101 NO. 6 / JUNE 2014safety endpoints comprised changes from baseline in hema-
tology, coagulation, biochemistry, lipids, ACTH, TSH, and
PRL, as well as serum levels of E2.Endometrial Histology
Endometrial biopsy samples were obtained 10–18 days after
menstruation start during screening, after treatment courses
1 and 4, and 3 months after the end of course 4 in women
with PAEC observed after course 4. All samples were assessed
in a blinded manner by three independent pathologists expe-
rienced in PAEC.Statistical Analysis
This study included open-label UPA treatment phases and
placebo-controlled double-blindedNETA phases where assess-
ments were considered exploratory. We planned to enroll 200
women, with approximately 80% of participants expected to
fulfill the efficacy endpoint of amenorrheaat the end of thefirst
UPA treatment course and allowing for a dropout rate of 10%
during the first course of treatment. The planned sample size
would provide an estimate of this percentage, with the corre-
sponding 95% confidence interval (CI) being less than 6%.
We considered 90 evaluable participants per treatment group
to be sufficient to enable a reliable exploration of any differ-
ences between NETA and placebo treatment. We conducted ef-
ficacy and safety analyses using all women who started
treatment course 1 (PEARL III open-label set) and two (PEARL
III extension full analysis set). Endpoints were summarized
using descriptive statistics. A 95% CI for the percentage of
amenorrheic women was produced using the Wilson score
method. The time from the start of dosing to amenorrhea was
summarized as a continuous variable and presented using the
Kaplan Meier probability estimates. The Wilcoxon rank sum
test was performed to compare the placebo versus NETA treat-
ment groups for the time to return to menstruation.
RESULTS
Patients
The baseline characteristics of the 209 participants who
entered the study, the 132 who entered the extension study,
and the 107 who received four treatment courses were very
similar; most women were in their late 30s or early 40s with
moderate to severe bleeding (the overall median PBAC was
>200), and self-reported pain or discomfort and/or anxiety
or depression (Table 1). Adverse events (eight women) and
lack of efficacy (four women) were infrequent causes of study
discontinuation (Supplemental Figs. 2 and 3).Efficacy
Menstrual bleeding. At the end of the first treatment course,
164 women (78.5%) were amenorrheic (95% CI, 72.4%–
83.5%; Supplemental Table 2). The median time to amenor-
rhea from treatment start was 3.5 days (interquartile range
[IQR], 2–6 days).
For the 132 women who entered the extension study to
receive multiple treatment courses, 88.5%, 88.2%, and1567
TABLE 1
Baseline (pretreatment course 1) characteristics for participants entering PEARL III and extension studies.
Characteristic
PEARL III only: open-label set
(baseline data for women who
started course 1), n[ 209
PEARL III and extension study:
full analysis set (baseline data
for women who started at least
two courses), n[ 132
PEARL III and extension study:
(baseline data for women who
started all four courses),
n[ 107
Age, mean  SD 40.1  6.0 40.5  5.8 40.8  5.5
Race, n (%)a
White 179 (85.6) 121 (91.7) 99 (92.5)
Black 19 (9.1) 8 (6.1) 5 (4.7)
Other 11 (5.3) 3 (2.3) 3 (2.8)
Body mass index, kg/m2, mean  SD 25.4  4.4 25.4  4.7 25.1  4.6
Median (IQR) PBAC (days 1–8) scoreb 216 (126, 401) 235 (142, 397) 234 (132, 368)
Median (IQR) total volume of three
largest fibroids, cm3
53.9 (24.0, 128.7) (n ¼ 207) 56.2 (25.7, 128.8) (n ¼ 132) 49.8 (26.9, 112.8) (n ¼ 107)
Median (IQR) uterine volume, cm3 199.6 (125.2, 291.3) (n ¼ 209) 200.7 (121.5, 303.1) (n ¼ 132) 178.6 (116.6, 278.7) (n ¼ 107)
Hemoglobin, g/dL, mean  SD 12.5  1.8 (n ¼ 199) 12.4  1.8 (n ¼ 127) 12.5  1.7 (n ¼ 105)
Short-Form McGill Pain questionnairec
assessment of pain, median (IQR)
8.0 (3.0, 17.0) (n ¼ 207) 8.0 (4.0, 19.0) (n ¼ 131) 8.0 (4.0, 19.0) (n ¼ 106)
Visual analog scale (VAS),d median (IQR) 38.0 (17.0, 63.0) (n ¼ 209) 36.0 (17.0, 63.5) (n ¼ 132) 37.0 (16.0, 63.0) (n ¼ 107)
UFS-QoL questionnairee
Symptom severity, mean  SD 47.7  17.7 (n ¼ 207) 49.2  17.7 (n ¼ 131) 49.0  16.6 (n ¼ 107)
Health-related QoL total score,
mean  SD
57.1  20.9 (n ¼ 208) 54.9  20.6 (n ¼ 132) 55.3  19.9 (n ¼ 107)
EQ-5D questionnaire n ¼ 209 n ¼ 132 n ¼ 107
Mobility (women with problems), n (%) 34 (16.3) 19 (14.4) 15 (14.0)
Self-care (women with problems), n (%) 5 (2.4) 2 (1.5) 1 (0.9)
Usual activities (women with problems),
n (%)
50 (23.9) 26 (19.7) 22 (20.6)
Pain/discomfort (women with moderate
or extreme symptoms), n (%)
154 (73.7) 102 (77.3) 84 (78.5)
Anxiety/depression (women with
moderate or extreme symptoms),
n (%)
129 (62.0f) 85 (64.9g) 74 (69.2)
VAS (health state),h mean  SD 67.5  18.6 67.9  18.5 68.2  17.6
Note: n ¼ Number of women with nonmissing observations.
a Race or ethnic group was reported by the investigator.
b PBAC, measured during days 1–8 at the start of the UPA treatment (course 1).
c Scores on the Short-Form McGill Pain questionnaire range from 0 to 45, with higher scores indicating more severe pain.
d Scores on VAS range from 0 to 100, with higher scores indicating more severe pain.
e On the UFS-QoL questionnaire, scores for symptom severity range from 0 to 100, with higher scores indicating increased severity. Total scores for health-related QoL range from 0 to 100, with
higher scores indicating a better QoL.
f n ¼ 208.
g n ¼ 131.
h Scores on VAS range from 0 to 100, with higher scores indicating a better health state.
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respectively (Table 2). The median times to amenorrhea after
the start of each course were 2, 3, and 3 days for courses 2,
3, and 4, respectively (Fig. 1A). The percentages of women
with only spotting or no bleeding were 93.9%, 94.1%, and
93.5% at the end of courses 2, 3, and 4, respectively.
After the end of each treatment course, menstruation
resumed. Menstrual bleeding (PBAC days 1–8) progressively
reduced from medians of 228 and 257 at the start of the first
course to 55 and 13 after the end of the fourth UPA course for
women randomized to placebo or NETA, respectively (P¼ .02;
Supplemental Table 3). Thus, 10-day progestin courses
reduced the magnitude of menstrual bleeding during the
off-treatment periods and also brought forward menstruation
return (e.g., median of 15 days instead of 30 days for women
receiving placebo after the end of the fourth UPA treatment
course; P< .001).
Fibroid volume. The median change from baseline to end of
the first UPA treatment course in the combined volume of1568the three largest fibroids was 45.1% (IQR, 66.1 to
24.9%; Supplemental Table 2). For women receiving multi-
ple treatment courses, fibroids continued to shrink, reaching a
median volume reduction of 72.1% after four treatment
courses (Table 2, Fig. 1B). This volume reduction was mostly
maintained (median 58.8%) at follow-up 3 months after
the end of the fourth treatment course. Of women completing
four treatment courses, 82.3% and 69.8%, respectively, had
R25% andR50% reductions in volume of the three largest
fibroids.
Pain and QoL. During the first treatment course, improve-
ments in pain were apparent from the fifth week onward
and were generally maintained for all UPA treatment periods
(Table 2, Supplemental Table 2). UFS-QoL scores indicated
substantially reduced QoL at baseline, but mean scores were
within the range of healthy participants at the end of each
treatment course and the improvement was largely main-
tained at 3-month follow-up after the final treatment course.
The EQ-5D questionnaire showed that most women hadVOL. 101 NO. 6 / JUNE 2014
TABLE 2
Efficacy results for participants entering PEARL III extension study (PEARL III extension full analysis set).a
Course 1 Course 2 Course 3 Course 4 3 Month follow-up
Amenorrhea, n/N (%) 105/132 (79.5) 116/131 (88.5) 105/119 (88.2) 96/107 (89.7) –
95% CI, % 71.9, 85.5 82.0, 92.9 81.2, 92.9 82.5, 94.2 –
Spotting or no bleeding, n/N (%) 117/132 (88.6) 123/131 (93.9) 112/119 (94.1) 100/107 (93.5) –
% Change in total volume of three largest
fibroidsb from baseline, median (IQR)
49.9 (69.0, 27.2) (n ¼ 130) 63.2 (76.4, 38.3) (n ¼ 119) 67.0 (79.9, 33.5) (n ¼ 106) 72.1 (86.6, 35.7) (n ¼ 96) 58.8 (79.2, 21.0) (n ¼ 97)
Total reductionR25%, n (%) 101 (77.7) 95 (79.8) 83 (78.3) 79 (82.3) 70 (72.2)
Total reductionR50%, n (%) 65 (50.0) 77 (64.7) 66 (62.3) 67 (69.8) 56 (57.7)
% Change in uterine volume from baseline,
median (IQR)
29.8 (45.2, 10.5) (n ¼ 132) 32.3 (47.1, 0.7) (n ¼ 121) 29.9 (47.5, 1.8) (n ¼ 107) 40.2 (55.6, 15.3) (n ¼ 96) 22.3 (46.2, 5.5) (n ¼ 99)
ReductionR25%, n (%) 73 (55.3) 73 (60.3) 61 (57.0) 64 (66.7) 45 (45.5)
Assessment of pain
Short-Form McGill Pain questionnaire n ¼ 131 n ¼ 119 n ¼ 108 n ¼ 96 n ¼ 96
Actual, median (IQR) 1.0 (0.0, 3.0) 1.0 (0.0, 4.0) 1.0 (0.0, 6.0) 1.0 (0.0, 2.0) 2.0 (0.0, 7.0)
Change from baseline, median (IQR) 7.0 (15.0, 2.0) 6.0 (14.0, 2.0) 5.0 (13.5, 0.0) 6.0 (16.0, 2.0) 4.0 (11.0, 0.0)
VASc n ¼ 132 n ¼ 120 n ¼ 109 n ¼ 96 n ¼ 98
Actual, median (IQR) 1.0 (0.0, 11.0) 3.0 (0.0, 13.5) 2.0 (0.0, 13.0) 1.5 (0.0, 8.5) 7.0 (1.0, 29.0)
Change from Baseline, median (IQR) 23.5 (58.0, 6.5) 27.5 (54.0, 7.0) 25.0, (49.0, 6.0) 30.5 (54.0, 10.0) 17.0 (42.0, 2.0)
UFS-QoL questionnaired
Symptom severity n ¼ 129 n ¼ 117 n ¼ 104 n ¼ 91 n ¼ 98
Actual, mean  SD 13.4  15.3 18.4  16.8 20.5  19.5 17.9  17.1 27.1  21.1
Change from baseline, mean  SD 35.8  21.2 30.5  21.9 27.7  23.3 30.0  20.3 21.2  22.1
Health-related QoL total score n ¼ 131 n ¼ 117 n ¼ 108 n ¼ 96 n ¼ 99
Actual, mean  SD 87.8  14.8 85.2  16.4 85.2  18.1 87.5  16.2 79.2  22.9
Change from baseline, mean  SD 32.8  21.9 29.6  22.4 29.4  23.4 31.4  21.6 22.7  22.5
EQ-5D questionnaire n ¼ 132 n ¼ 121 n ¼ 109 n ¼ 96 n ¼ 99
Mobility (women with problems), n (%) 6 (4.5) 3 (2.5) 5 (4.6) 4 (4.2) 3 (3.0)
Self-care (women with problems), n (%) 0 0 1 (0.9) 0 0
Usual activities (women with problems), n (%) 6 (4.5) 3 (2.5) 4 (3.7) 3 (3.1) 7 (7.1)
Pain/discomfort (women with moderate or
extreme symptoms), n (%)
33 (25.2e) 31 (25.6) 26 (24.1f) 23 (24.0) 37 (37.4)
Anxiety/depression (women with moderate or
extreme symptoms), n (%)
49 (37.1) 27 (22.3) 33 (30.3) 29 (30.2) 37 (37.4)
VAS (health state)g n ¼ 132 n ¼ 120 n ¼ 109 n ¼ 95 n ¼ 99
Actual, mean  SD 78.1  18.0 81.2  14.9 83.4  13.5 84.4  15.5 84.1  14.9
Change from baseline, mean  SD 10.2  23.8 13.3  21.3 15.6  20.2 15.2  20.3 14.8  18.9
Note: n ¼ Number of women with nonmissing observations.
a Amenorrhea (and spotting or no bleeding) assessed while under UPA treatment. For remaining results, courses 1 and 4 data were collected at the end of UPA treatment; courses 2 and 3 data were collected after the first menstrual bleed after UPA treatment and
subsequent NETA/placebo treatment.
b The same three fibroids identified at screening were followed throughout the study.
c Scores on VAS range from 0 to 100, with higher scores indicating more severe pain.
d On the UFS-QoL questionnaire, scores for symptom severity range from 0 to 100, with higher scores indicating increased severity. Total scores for health-related QoL range from 0 to 100, with higher scores indicating a better QoL.
e n ¼ 131.
f n ¼ 108.
g Scores on VAS range from 0 to 100, with higher scores indicating a better health state.
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FIGURE 1
(A) Time to no bleeding (persistent amenorrhea; PEARL III extension
full analysis set). Time to amenorrhea was defined as the first day
for which there was subsequently no bleeding for longer than
35 days to the end of UPA treatment within each treatment course,
assessed using the patient diary data from the date of the first dose
of UPA (day 0, which was to be within the first 4 days of the start
of menstruation for treatment courses 1 and 2 and on the first day
of menstruation for treatment courses 3 and 4). One day of
spotting in any 35-day interval was accepted. Circles denote
censored observation (i.e., a participant had a subsequent interval
of 35 days or less up to the end of UPA treatment for which no
more than 1 day of spotting was observed). (B) Percent change
from baseline in total volume of the three largest fibroids (PEARL III
extension full analysis set). N ¼ number of women with nonmissing
observations. The same three fibroids identified at screening were
followed throughout the study. Box extends to 25th and 75th
percentiles (IQR) and shows median value. Mean values are also
plotted. Whiskers extend to 10th and 90th percentiles. Courses 1
and 4 data were collected at the end of UPA treatment; courses 2
and 3 data were collected after the first menstrual bleed after UPA
treatment and subsequent NETA/placebo treatment.
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SEMINAL CONTRIBUTIONdiscomfort or pain and/or anxiety and depression at baseline,
but few women reported these conditions at the end of each
UPA treatment course and at 3-month follow-up (Tables 1
and 2).
Surgery and enrollment in extension study. A total of 132/
209 patients consented and proceeded to the extension phase
of the study. Among them were 64/91 women for whom sur-
gery was planned at baseline (Supplemental Fig. 2). There
were no significant differences in baseline disease severity be-
tween women who entered the extension study and those who
did not.
After one course of treatment, UPA exerted similar con-
trol over bleeding and pain for patients entering the extension1570study (compared with those who did not). Women entering
the extension study had a somewhat greater reduction in me-
dian fibroid volume (49.9% vs. 38.5%) and greater
improvement in UFS-QoL (least square mean change, 31.2
vs. 25.3) after one course of UPA compared with those who
did not enter the second study (Supplemental Table 4).Safety
General safety. There were no serious adverse events
(SAEs) reported during the first course of UPA treatment,
but two women had three post-treatment SAEs (two epi-
sodes of uterine bleeding and one breast cancer) that
were considered not related to study medication. Seven
women who entered the extension study (and received mul-
tiple courses of treatment) reported SAEs (five cases of
uterine bleeding, one thyroid cyst, and one chlamydia
infection; Table 3).
During the first course of UPA treatment, TEAEs occurred
in 120 women (57.4%; Supplemental Table 5), but only eight
women (3.8%) had severe AEs. Only one TEAE (headache) led
to treatment withdrawal. TEAEs occurring in >5% of women
were headache (16.3%), nasopharyngitis (6.7%), and abdom-
inal pain (5.3%). In women receiving multiple treatment
courses, headaches, nasopharyngitis, abdominal pain, and
hot flashes were the most frequent TEAEs, but the incidence
did not increase over time and only five women discontinued
UPA because of TEAEs (Table 3).
There were no safety signals arising from physical exam-
ination, vital signs, liver function, and other laboratory safety
tests, hormone levels, ovarian ultrasound, and ECGs (see
Supplemental Table 6).
Endometrial safety. Transient increases in endometrial
thickness occurred in less than 10% of women after each
UPA course (Supplemental Table 6). No cases of endometrial
hyperplasia or adenocarcinoma were reported at any time
point for any woman.
Nonphysiological features were reported by at least two
pathologists for 18/171 (11%), 45/176 (26%), and 22/87
(25%) women biopsied at screening and at approximately
6 weeks after courses 1 and 4, respectively (Supplemental
Table 7). Fifteen women with PAEC diagnosed after the fourth
UPA course were rebiopsied 3 months later; only three had
some nonphysiological features. Ten days of NETA did not
have a significant impact on the incidence of nonphysiolog-
ical changes induced by UPA.DISCUSSION
In these sequential studies of women with fibroids and exces-
sive menstrual bleeding, we administered intermittent courses
of UPA. Women had the option of surgery after one course,
but for many women the goal is to avoid surgery and most
decided to enroll into the extension study where they could
receive up to three additional courses even if surgery was
planned at baseline. Intermittent UPA (administered over an
18-month period) induced high rates of amenorrhea (nearly
90% during repeat treatment courses), confirming its ability
to control for the long term the most troublesome symptomVOL. 101 NO. 6 / JUNE 2014
TABLE 3
Adverse events (PEARL III extension safety set).a
Adverse event, no. of women (%)
Overall
(n[ 132)
Course 1
(n[ 132)
Course 2
(n[ 131)
Course 3
(n[ 119)
Course 4
(n[ 107)
SAEs
At least one SAE 7 (5.3) 0 2 (1.5) 2 (1.7) 3 (2.8)
Any SAE during UPA treatment 6 (4.5) 0 2 (1.5) 2 (1.7) 2 (1.9)
HMB 2 (1.5) 0 1 (0.8) 0 1 (0.9)
Uterine hemorrhage 2 (1.5) 0 1 (0.8) 0 1 (0.9)
Metrorrhagia 1 (0.8) 0 0 1 (0.8) 0
Thyroid cyst 1 (0.8) 0 0 1 (0.8) 0
Any SAE during NETA/placebo treatment 0 0 0 0 0
Any SAE off treatment 1 (0.8) 0 0 0 1 (0.9)
Chlamydial infection 1 (0.8) 0 0 0 1 (0.9)b
Adverse eventsc
Leading to study withdrawald 5 (3.8) 0 1 (0.8) 2 (1.7) 2 (1.9)
At least one event 91 (68.9) 73 (55.3) 27 (20.6) 35 (29.4) 37 (34.6)
Headache 26 (19.7) 19 (14.4) 4 (3.1) 6 (5.0) 7 (6.5)
Nasopharyngitis 18 (13.6) 10 (7.6) 3 (2.3) 1 (0.8) 6 (5.6)
Abdominal pain (including upper/lower) 12 (9.1) 7 (5.3) 3 (2.3) 1 (0.8) 2 (1.9)
Hot flashes 12 (9.1) 7 (5.3) 1 (0.8) 5 (4.2) 1 (0.9)
Back pain 8 (6.1) 2 (1.5) 0 4 (3.4) 2 (1.9)
Fatigue 8 (6.1) 4 (3.0) 0 3 (2.5) 3 (2.8)
Nausea 8 (6.1) 4 (3.0) 2 (1.5) 1 (0.8) 1 (0.9)
Vertigo 7 (5.3) 6 (4.5) 0 1 (0.8) 1 (0.9)
Hair loss 6 (4.5) 5 (3.8) 1 (0.8) 2 (1.7) 0
Breast discomfort/breast pain/breast tenderness 6 (4.5) 4 (3.0) 0 1 (0.8) 1 (0.9)
a All SAEs and all adverse events that occurred during UPA treatment in at least 4% of women overall are included.
b SAE was diagnosed 3 months after treatment course 4.
c Adverse events with onset on or after the first dose of UPA and before the first dose of NETA/placebowithin each treatment course or up to and including 7 days after the last dose of UPA if NETA/
placebo was never started.
d In addition, another adverse event that occurred when a woman was not receiving UPA led to study withdrawal.
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Fertility and Sterility®of fibroids for most women. The previously reported efficacy
of UPA in shrinking fibroids was also confirmed, and there
was further fibroid shrinkage with successive treatment
courses with no evidence of rapid rebound growth. However,
even in women with little or no fibroid shrinkage, UPA still
induced high rates of bleeding control (Supplemental
Table 8). Women also reported substantial improvements in
pain, anxiety and depression, and QoL during treatment.
The UFS-QoL scores at baseline were slightly less severe
than reported in some previous studies of patients undergoing
invasive treatments; however, at the end of each UPA course,
symptom severity and QoL scores were similar to those
reported at follow-up for patients who underwent hysterec-
tomy, myomectomy, uterine artery embolization, high-
intensity focused ultrasound, or experimental treatment
with mifepristone (23–26).
It might have been expected that fibroid-related symp-
toms would partially return during off-treatment periods,
but the magnitude of menstrual bleeding (after the end of
each treatment course) progressively diminished. Moreover,
at 3 months after the last treatment course, the reduction
in fibroid volume and the improvements in pain and QoL
were largely maintained. These findings, together with pre-
vious observations (11) that UPA can induce apoptosis and
decrease proliferation in fibroid cells, suggest that long-
term intermittent SPRM therapy could result in disease
regression.
Most adverse events were mild or moderate and did not
increase in frequency with successive treatment courses.VOL. 101 NO. 6 / JUNE 2014The most frequently reported SAE was excessive uterine
bleeding, but considering that women were monitored for
over 18 months, the incidence of this finding is not greater
than that reported in previous studies of UPA, placebo, and
comparator agents in women with fibroid-related HMB
(13, 14).
Some of the nonphysiological features of PAEC can be
observed in women of reproductive age in the absence of
pharmacotherapy (>10% incidence at screening in this study)
(18). Donnez et al. previously reported that 3-month courses
of UPA induce PAEC in approximately 60% of women and
that this is fully reversible 6 months after the end of the treat-
ment (13, 14). In this study, the endometrium was biopsied
approximately 6 weeks after the end of the first and fourth
courses of UPA treatment, and PAEC was diagnosed in
approximately 25% of women at both time points. Similar
incidences of PAEC after one and four courses of treatment
indicate that treatment duration and cumulative dose do
not affect occurrence of PAEC during prolonged,
intermittent UPA administration. In the small subgroup of
women with PAEC diagnosed after the fourth UPA course,
the PAEC diagnosis rate at 3 months follow-up was the
same as at screening, confirming that PAEC is rapidly revers-
ible inmost women after successive on/off administration. No
cases of endometrial hyperplasia or adenocarcinoma were
observed.
A 10-day course of progestin, administered immedi-
ately after each UPA treatment course, did not affect
PAEC but was associated with a significantly reduced and1571
SEMINAL CONTRIBUTIONan earlier occurrence of menstrual bleeding during the
off-treatment periods. However, these findings are prob-
ably insufficient to suggest that progestins should be
routinely used in conjunction with UPA treatment unless
there is a need to control the timing or amount of men-
strual bleeding, for example, before a planned invasive
procedure.
Currently, there are no approved long-term medical
treatment options for the management of women with
symptomatic fibroids. Some clinicians have attempted to
use GnRH agonists with hormonal add-back therapy, but
women still have menopausal symptoms, rates of bone
mass loss may not be entirely mitigated, and fibroids rapidly
enlarge after treatment is stopped (7). There are abundant P
receptors in fibroids, and oral progestins (alone) have been
used but without evidence that they shrink fibroids and
with risk of breakthrough bleeding (27, 28). Intrauterine
levonorgestrel does not consistently reduce fibroid volume,
and its efficacy in women with submucous fibroids or a
distorted uterus is controversial (8). Thus our results
suggest that intermittent UPA could become the first long-
term medical management option for many women with
symptomatic fibroids.
There are some limitations to our study. We could not use
an active or placebo control for long-term UPA treatment.
However, it was previously demonstrated that a 3-month
course of UPA was superior to placebo and noninferior to a
GnRH agonist for control of HMB (13, 14). The dose (10 mg)
and duration of each UPA course (3 months) were based on
previous experience, but it is unknown whether longer
periods of continuous treatment could also be safe and
effective. We also recruited relatively few black
participants, but previous studies reported efficacy in these
women (13, 14, 29, 30). We also restricted fibroid size to a
maximum diameter of 10 cm, but we note that the median
diameter of the largest fibroid in a series of patients
undergoing hysterectomy, myomectomy, or uterine artery
embolization was 6 cm (24). Approximately one-third of
women (some of whom had surgery) did not enroll in the
extension study, and so we cannot be certain how this subset
of patients would have responded to repeated UPA treatment
courses. Womenwho received only one UPA treatment course
achieved similar levels of bleeding control to those partici-
pating in the extension study, although improvements in
QoL and fibroid volume reduction were slightly less
substantial.
In conclusion, repeated 3-month courses of oral UPA
10 mg once daily effectively control bleeding and pain,
reduce fibroid volume, and restore QoL over the long term
in many women with symptomatic fibroids, providing an
effective and well-tolerated long-term medical treatment
for fibroids.
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MATERIALS AND METHODS
Study Population
Dates of the study period. PEARL III only: July 13, 2010, to
November 10, 2011.
PEARL III þ PEARL III extension: July 13, 2010 to
January 24, 2013.
The study ended after the last follow-up of the last patient
as foreseen in the protocol.
Principal exclusion criteria. The principal exclusion criteria
for the study are listed in Supplemental Table 1. The body
mass index was calculated using the body weight in kilo-
grams divided by the height in meters squared.
Randomization and masking. All women received open-
label treatment with UPA. UPA treatment courses were equal
to 90 days of UPA treatment. Women consented to participate
to one treatment course (PEARL III study). Approximately
8 weeks into treatment course 1, women were randomized
to receive double-blind treatment with either NETA or match-
ing placebo after a predefined order and according to a prede-
fined randomization list that had been established by the
designated unblinded statistician at MDSL International
with the corresponding treatment supplied at the end of the
first course of UPA. The NETA or placebo were packaged in
blisters of identical appearance. The treatment packs were as-
signed within each site by the investigator to the subjects in
sequential order starting from the lowest number to the high-
est number.
After completion of the first treatment period, patients
were proposed to participate in an extension study (PEARL
III extension) with three further UPA treatment courses. The
women received the same double-blind treatment of NETA
or placebo throughout all treatment courses. Double-blinding
was maintained for women and investigators throughout the
entire study. At the end of the PEARL III study, the blind was
broken for selected sponsor members to fulfill regulatory
reporting requirements.1573.e1Efficacy Endpoints
Assessment of menstrual bleeding. The proportion of
women in amenorrhea at the end of each UPA treatment
course and the time to onset of amenorrhea for each treatment
course were evaluated. Amenorrhea was defined as no
bleeding for a continuous period of at least 35 days. Within
any 35-day interval, 1 day of spotting was accepted. To assess
this endpoint, we used a simplified semiquantitative bleeding
scale, which included four categories: ‘‘no bleeding,’’ ‘‘spot-
ting,’’ ‘‘bleeding,’’ or ‘‘heavy bleeding.’’ During the first treat-
ment course the diary was completed daily with four
categories available, whereas during subsequent treatment
courses, women only reported spotting, bleeding, or heavy
bleeding on days when these occurred (Supplemental
Fig. 4A and B show sample charts). The proportion of women
with ‘‘spotting’’/‘‘no bleeding’’ (that is, no ‘‘bleeding’’ or
‘‘heavy bleeding’’) and the time to onset of ‘‘spotting’’/‘‘no
bleeding’’ for each treatment course was also evaluated.
The PBAC (1–4), an instrument that estimates menstrual
blood loss in a semiquantitative measure, was used to
evaluate the magnitude of menstrual bleeding at the start of
the first treatment cycle and during the off-treatment period
after each treatment course. PBAC has been widely used for
evaluating drugs or devices interfering with menstrual
bleeding such as desmopressin (5), tranexamic acid (6), orme-
loxifene (7), levonorgestrel intrauterine device (8), and de-
vices for endometrial ablation (9). The possible score ranges
from 0 to more than 500 (with no defined upper limit), with
higher scores indicating a greater severity of bleeding. Scores
greater than 100 indicate HMB (1). Standardized sanitary ma-
terials were provided, and women recorded the number of
tampons or pads used and the extent of soiling with blood.
A sample chart is presented in Supplemental Figure 4C. The
PBAC was completed by women during the first 8 days of
their menstrual cycle at the start of treatment course 1 to
have an objective assessment of the bleeding intensity and
during the first 8 days of the first menstrual cycle after each
NETA/placebo treatment.
Secondary efficacy endpoints. The volume of the three
largest fibroids was assessed using transvaginal ultrasound
(TVUS). The same three fibroids identified during screening
were followed throughout the study. TVUS also included an
assessment of the ovaries, uterine volume, endometrial
thickness, and deformation of the uterine cavity and was
performed at baseline, at the end of UPA treatment for
course 1, and for subjects continuing in the extension
study: 2 weeks after the start of first menses after treatment
courses 2 and 3, at the end of UPA treatment course 4, and
approximately 3 months after the end of the final treatment
course.
Pain was measured with the Short-Form McGill Pain
questionnaire (SF-MPQ) (10). The SF-MPQ part A consists
of 15 descriptors that are ranked on an intensity scale of
0 ¼ none to 3 ¼ severe. Descriptors 1–11 represent the sen-
sory (S) dimension of the pain experience, and 12–15 repre-
sent the affective (A) dimension. The total score for S is
obtained by adding the ranks from descriptors 1–11. The total
score for A is obtained by adding the ranks from descriptorsVOL. 101 NO. 6 / JUNE 2014
Fertility and Sterility®12–15. The overall total score is then obtained by adding the
scores for S and A. If either the score for A or S is missing, then
the overall total score will also be missing. Scores for SF-MPQ
part A range from 0 (no pain) to 45 (severe pain for every S
and A descriptor). SF-MPQ part B consists of a visual analog
scale (VAS), with the resulting score between 0 mm and
100 mm; scores range from 0 (no pain) to 100 (worst possible
pain). The SF-MPQ was assessed at baseline, at the end of
weeks 4 and 8, and at the end of UPA treatment for the first
treatment course, as well as for subjects continuing in the
extension study 2 weeks after the start of first menses after
treatment courses 2 and 3, at the end of UPA treatment for
course 4, and approximately 3 months after the end of the
final treatment course.
QoL was assessed using the Uterine Fibroid Symptom
and Health-Related Quality of Life (UFS-QoL) questionnaire
(11). The UFS-QoL is a validated, disease-specific question-
naire that consists of two parts; [1] a symptom severity score
that includes bleeding, abdominal pressure, urination fre-
quency, and fatigue (range, 0–100) with high symptom
severity scores indicating increased symptom severity; and
[2] a health-related quality of life (HRQL) total score. The
HRQL total score (range, 0–100) is composed of six domains:
Concern, Activities, Energy/Mood, Control, Self-Conscious,
and Sexual Function. High HRQL scores indicate better
QoL. Furthermore, another measure of QoL was assessed us-
ing the EQ-5D questionnaire, a standardized instrument for
use as a measure of health outcome that consists of five di-
mensions of health status: mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression, all with a
three-level scale. It also includes a VAS ranging from zero
to 100, with lower scores indicating a worse health state.
QoL assessments were recorded at the same time points as
the volume of fibroids.Safety Endpoints
All biopsy samples were processed at a central location and
were assessed by three independent pathologists who were
unaware of the study group assignments, the visit sequence,
and one another's assessment. All pathologists have partic-
ipated in previous UPA studies (12). Assessments were made
according to standard diagnostic criteria and terminology
for nonphysiological endometrial changes (p-receptor
modulator–associated endometrial changes or PAEC), as
described elsewhere by Mutter and colleagues (13). A
consensus diagnosis of PAEC was made if two or more pa-
thologists observed nonphysiological changes in an endo-
metrial biopsy specimen. The timing of endometrial
biopsies is presented in Supplemental Figure 1. Additional
samples could be taken if endometrial thickness was
>18 mm or if judged necessary by the investigator.
Clinical laboratory testing (hematology, biochemistry,
and coagulation) was performed in a central laboratory
(ICON Central Laboratories Ltd.) using validated assays. Lab-
oratory investigations and vital signs were assessed at all
visits. Serum E2, ACTH TSH and PRL levels were measured
at screening, at the end of UPA treatment for courses 1
and 4, 2 weeks after the start of first menses after treatmentVOL. 101 NO. 6 / JUNE 2014course 2, and approximately 3 months after the end of the
final treatment course. The FSH level was measured at
screening.Statistical Analyses
Data management and statistical analysis were conducted us-
ing SAS 9.2 and governed by a comprehensive quality assur-
ance system following International Conference on
Harmonisation (14) and other applicable regulatory
guidelines.
RESULTS
Supplemental Table 2 presents efficacy results for the first
treatment course in the PEARL III open-label set.
The individual decisions on whether to have surgery or
enter the extension study and to continue successive treat-
ment courses may depend on many factors including advice
of the investigator or surgeon, the response to treatment,
and the patient's own preference for continued treatment
and to adhere to all the study visits and procedures. The
women's baseline characteristics and the overall response
to course 1 (amenorrhea, fibroid volume reduction, pain,
and QoL) were similar for women who continued into the
extension study compared with all women who started
PEARL III. Only four women discontinued PEARL III exten-
sion owing to lack of efficacy, and an analysis (not shown)
of women who completed all four courses of treatment in-
dicates that there were improvements in amenorrhea rates
and fibroid volume reduction with successive treatment
courses.
Supplemental Table 3 presents a summary of volume and
timing of first menstruations during off-treatment periods for
the PEARL III double-blind set (all women who received NETA
or placebo at the end of UPA treatment for treatment course 1)
and the PEARL III extension full analysis set), split by the
NETA and placebo treatment groups and overall.
Supplemental Table 8 presents the proportion of women
in amenorrhea at the end of each treatment course according
to whether the total volume of the three largest fibroids was
reduced byR 25%.
Supplemental Table 4 presents a summary of relevant ef-
ficacy results after the first UPA treatment course comparing
women not entering the PEARL III extension study with those
who decided to participate in an extension study with up to
three additional treatment courses. Both subgroups had
similar disease severity at baseline and efficacy response to
one course of UPA.
Supplemental Table 5 presents a summary of adverse
events in the PEARL III safety set (for the first treatment
course).
Five women discontinued the extension study owing to
adverse events. These were women with heavy uterine
bleeding (n ¼ 1) after the end of course 2, metrorrhagia
(n¼ 1) during course 3, vertigo/dyspepsia/abdominal cramps
and constipation during course 3, high blood pressure (n ¼ 1)
during course 4, and heavy uterine bleeding (n ¼ 1) during
course 4. Another woman discontinued the study due to leg
pain that started 2 months after the end of course 2.1573.e2
SEMINAL CONTRIBUTIONSupplemental Table 7 shows a summary of pathologist
consensus of nonphysiological histological features in the
endometrium.
Supplemental Tables 6 and 9 present summaries of other
safety assessments in the PEARL III safety set and the PEARL
III extension safety set.
Supplemental Figure 5 presents the time to spotting/no
bleeding for each treatment course for the PEARL III exten-
sion full analysis set.
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SUPPLEMENTAL FIGURE 1
Pictorial flow diagram of treatments and biopsies for PEARL III and extension study.
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SUPPLEMENTAL FIGURE 2
251 Consented and Screened
Patient disposition for participants entering PEARL III and PEARL III
extension. aIncludes one woman who was withdrawn owing to an
adverse event occurring in an off-treatment period. bOne woman
was treated correctly for treatment course 1 but received only
placebo medication (no UPA) in error for treatment course 2.
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SUPPLEMENTAL FIGURE 3
Patient disposition for participants entering PEARL III and PEARL III extension, including details for NETA/placebo treatment groups. aOne woman
was treated correctly for treatment course 1 but received only placebo medication (no UPA) in error for treatment course 2. bIncludes one woman
who was withdrawn owing to an adverse event occurring in an off-treatment period.
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SUPPLEMENTAL FIGURE 4
Assessment of uterine bleeding. (A) Semiquantitative bleeding scale used in PEARL III. (B) Semiquantitative bleeding scale used in PEARL III
extension. (C) Example of a completed PBAC showing a score of 320 (equivalent to a menstrual blood loss of approximately 250 mL).
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SUPPLEMENTAL FIGURE 4 Continued
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SUPPLEMENTAL FIGURE 5
Time to spotting/no bleeding (PEARL III extension full analysis set).
Time to spotting/no bleeding was defined as the first day for which
there was subsequently only spotting or no bleeding for longer
than 35 days to the end of UPA treatment within each treatment
course, assessed using the patient diary data from the date of the
first dose of UPA (day 0, which was to be within the first 4 days of
the start of menstruation for treatment courses 1 and 2 and on the
first day of menstruation for treatment courses 3 and 4). Circles
denote censored observation (i.e., a woman had a subsequent
interval of 35 days or less up to the end of UPA treatment for
which only spotting or no bleeding was observed).
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SUPPLEMENTAL TABLE 1
Key exclusion criteria.
Previous uterine surgery including endometrial ablation or uterine artery embolization.
History of or current uterus, cervix, ovarian, or breast cancer.
Significant finding on Papanikolaou test (PAP) smear within the past 12 months.
Endometrium hyperplasia or adenocarcinoma within the past 6 months or similar lesions in the screening biopsy. In case of biopsies older than
6 months, these had to be repeated.
Large uterine polyp (>2 cm).
Calcified fibroids and/or a calcified uterus.
Severe coagulation disorder.
One or more ovarian cystsR4 cm diagnosed by ultrasound.
History of treatment for fibroid with an SPRM, including UPA.
Treatments with progestins (systemic or progestin-releasing intrauterine system), oral contraceptive, acetylsalicylic acid, mefenamic acid,
anticoagulants such as cumarins and/or antifibrinolytic drugs such as tranexamic acid, P antagonists, systemic glucocorticoid treatments and/or
systemic depot glucocorticoid, treatments that contain PgP substrate (digoxin, fexofenadine) or contain moderate or potent inhibitors or
inducers of CYP3A4.
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SUPPLEMENTAL TABLE 2
Efficacy results for first treatment course (PEARL III open-label set;
n[ 209).
Assessment n Resulta
Amenorrhea
No. of women in
amenorrhea (%)
209 164 (78.5)
95% CI, % 209 72.4, 83.5
Spotting/no bleeding
No. of women with
spotting or no
bleeding (%)
209 181 (86.6)
95% CI 209 81.3, 90.6
Total volume of three largest
fibroidsb
% Change from baseline,
median (IQR)
194 45.1 (66.1, 24.9)
Total reductionR25%, n
(%)
194 145 (74.7)
Total reductionR50%, n
(%)
194 86 (44.3)
Uterine volume
% Change from baseline,
median (IQR)
201 28.9 (45.5, 8.4)
ReductionR25%, n (%) 201 109 (54.2)
Assessment of pain
SF-MPQc
End of week 4 actual,
median (IQR)
204 2.0 (0.0, 4.0)
End of week 4 change
from baseline, median
(IQR)
202 5.0 (12.0, 1.0)
End of week 8 actual,
median (IQR)
198 0.0 (0.0, 2.0)
End of week 8 change
from baseline, median
(IQR)
196 6.0 (14.0, 1.6)
End of course 1 actual,
median (IQR)
200 1.0 (0.0, 3.0)
Course 1 change from
baseline, median (IQR)
198 6.0 (14.0, 2.0)
Visual analog scale (VAS)d
End of week 4 actual,
median (IQR)
204 8.0 (0.0, 28.0)
End of week 4 change
from baseline, median
(IQR)
204 21.0 (39.0, 2.0)
End of week 8 actual,
median (IQR)
202 2.0 (0.0, 12.0)
End of week 8 change
from baseline, median
(IQR)
202 26.0 (54.0, 7.0)
Course 1 actual, median
(IQR)
200 1.0 (0.0, 12.0)
Course 1 change from
baseline, median (IQR)
200 24.5 (54.0, 6.0)
UFS-QoL questionnairee
Symptom severity
Actual, mean  SD 196 14.5  15.5
Change from baseline,
mean  SD
194 33.3  21.5
Health-Related QoL total
score
Actual, mean  SD 201 86.2  15.6
Change from baseline,
mean  SD
200 29.2  22.4
EQ-5D questionnaire
Mobility (women with
problems), n (%)
201 10 (5.0)
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Continued.
Assessment n Resulta
Self-care (women with
problems), n (%)
201 0 (0.0)
Usual activities (women
with problems), n (%)
200 12 (6.0)
Pain/discomfort (women
with moderate/
extreme symptoms), n
(%)
200 60 (30.0)
Anxiety/depression
(women with
moderate/extreme
symptoms), n (%)
201 84 (41.8)
VAS (health state)f
Actual, mean  SD 200 76.8  17.6
Change from baseline,
mean  SD
200 9.6  23.3
Note: n ¼ Number of women with nonmissing observations.
a Assessments were made at end of a 13-week treatment course of UPA and before 10-day
treatment course of NETA/placebo, except for the SF-MPQ, which was also assessed after 4
and 8 weeks of treatment.
b The same three fibroids identified at screening were followed throughout the study.
c Scores on the SF-MPQ range from 0 to 45, with higher scores indicating more severe pain.
d Scores on the VAS of the SF-MPQ range from 0 to 100, with higher scores indicating more
severe pain.
e Scores on the VAS of the EQ-5D range from 0 to 100, with higher scores indicating a better
health state.
f On the UFS-QoL questionnaire, scores for symptom severity range from 0 to 100, with
higher scores indicating increased severity. Total scores for health-related QoL range from
0 to 100, with higher scores indicating a better QoL.
Donnez. Long-term treatment of uterine fibroids. Fertil Steril 2014.
1573.e11 VOL. 101 NO. 6 / JUNE 2014
SEMINAL CONTRIBUTION
SUPPLEMENTAL TABLE 3
Summary of PBAC at the start of treatment course 1 and PBAC and timing of first menstruation after each treatment course.
Total UPA then placebo UPA then NETA P valuea
PEARL III (double-blind set) n ¼ 201 n ¼ 103 n ¼ 98
PBAC score (days 1–8 of first menses)b
Postscreening, median
(IQR)
216 (126, 376) 218 (126, 344) 206 (131, 422)
Post-treatment course 1 n ¼ 194 n ¼ 99 n ¼ 95
Actual, median (IQR) 98 (36, 211) 123 (51, 248) 75 (27, 179)
Change, median (IQR) 92 (220, 23) 69 (167, 40) 122 (299, 9) .01
Time to return to menstruation, daysc
Post-treatment course 1 n ¼ 196 n ¼ 101 n ¼ 95
Median (IQR) 18 (14, 26) 25 (20, 29) 14 (13, 15) < .0001
PEARL III extension (full
analysis set)
n ¼ 132 n ¼ 69 n ¼ 63
PBAC score (days 1–8 of first menses)b
Post-screening, median
(IQR)
235 (142, 397) 228 (142, 139) 257 (140, 498)
Post-treatment course 1 n ¼ 131 n ¼ 69 n ¼ 62
Actual, median (IQR) 94 (31, 210) 123 (53, 233) 59 (21, 155)
Change, median (IQR) 120 (264, 5) 92 (171, 25) 144 (367, 42) .006
Post-treatment course 2 n ¼ 123 n ¼ 65 n ¼ 58
Actual, median (IQR) 64 (20, 168) 84 (18, 226) 54 (21, 103)
Change, median (IQR) 150 (255, 55) 127 (211, 14) 171 (372, 71) .01
Post-treatment course 3 n ¼ 114 n ¼ 58 n ¼ 56
Actual, median (IQR) 42 (14, 138) 75 (22, 191) 28 (9, 66)
Change, median (IQR) 131 (311, 59) 103 (186, 36) 224 (461, 104) < .0003
Post-treatment course 4 n ¼ 89 n ¼ 49 n ¼ 40
Actual, median (IQR) 31 (11, 100) 55 (22, 136) 13 (6, 48)
Change, median (IQR) 120 (255, 45) 97 (184, 31) 166 (356, 74) .02
Time to return to menstruation, daysc
Post-treatment course 1 n ¼ 131 n ¼ 69 n ¼ 62
Median (IQR) 18 (14, 27) 25 (20, 30) 14 (13, 15) < .0001
Post-treatment course 2 n ¼ 125 n ¼ 66 n ¼ 59
Median (IQR) 18 (14, 27) 26 (21, 34) 14 (13, 17) < .0001
Post-treatment course 3 n ¼ 116 n ¼ 60 n ¼ 56
Median (IQR) 21 (14, 31) 30 (24, 36) 14 (13, 17) < .0001
Post-treatment course 4 n ¼ 99 n ¼ 53 n ¼ 46
Median (IQR) 22 (15, 34) 30 (23, 35) 15 (14, 18) < .0001
a Tests comparing NETA to placebo were conducted using the Wilcoxon rank sum test.
b PBAC score postscreening assessment measured during days 1–8 at start of UPA treatment course 1. Score post-treatment course assessments measured during days 1–8 of first menstruation
after the end of the respective treatment course.
c Excludes women in whom surgery was performed before return of menstruation or women discontinued before return of menstruation.
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SUPPLEMENTAL TABLE 4
Selected efficacy results for participants not entering/entering the PEARL III extension study.
Did not enter extension Entered extension Difference Statisticsa
Amenorrhea, n/N (%)b 59/77 (76.6) 105/132 (79.5) (2.9) .73
95% CI, % 66.0, 84.7 71.9, 85.5 8.8, 14.6
Spotting or no bleeding, n/N
(%)b
64/77 (83.1) 117/132 (88.6) (5.5) .30
95% CI, % 73.2, 89.9 82.1, 93.0 4.4, 15.5
Total volume of three largest
fibroidsc
n ¼ 64 n ¼ 130
% Change from baseline 38.5 49.9 12.1 .01
95% CI, % 47.8, 29.0 56.7, 42.5 22.2, 2.7
Uterine volume n ¼ 69 n ¼ 132
% Change from baseline 27.0 29.8 1.4 .79
95% CI, % 33.9, 14.5 35.3, 22.6 10.1, 7.5
Assessment of pain
VASd n ¼ 68 n ¼ 132
Change from baseline 27.5 23.5 3.0 .53
95% CI, % 36.0, 13.0 34.0, 17.0 12.0, 6.0
UFS-QoL questionnairee
Symptom severity n ¼ 65 n ¼ 129
Change from baseline 28.4 35.8
Least square mean 30.6 34.7 4.1 .08
95% CI, % 34.3, 26.8 37.3, 32.0 8.7, 0.5
Health-related QoL total
score
n ¼ 69 n ¼ 131
Change from baseline 22.2 32.8
Least square mean 25.3 31.2 5.9 .009
95% CI, % 21.7, 28.8 28.6, 33.8 1.5, 10.3
a Fisher's exact test was used for amenorrhea and spotting or no bleeding; Wilcoxon rank sum test was used for total volume of three largest fibroids, uterine volume, assessment of pain (medians
reported), and analysis of covariance for the UFS-QoL questionnaire (means reported).
b Amenorrhea (and spotting or no bleeding) assessed while under UPA treatment. For remaining results, data were collected at the end of UPA treatment.
c The same three fibroids identified at screening were followed throughout the study.
d Scores on VAS range from 0 to 100, with higher scores indicating more severe pain.
e On the UFS-QoL questionnaire, scores for symptom severity range from 0 to 100, with higher scores indicating increased severity. Total scores for health-related QoL range from 0 to 100, with
higher scores indicating a better QoL.
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SUPPLEMENTAL TABLE 5
Adverse events (PEARL III safety set; n[ 209).a
Adverse event No. of women (%)
SAEs
At least one SAE 2 (1.0)
Any SAE during UPA treatment 0
Any SAE during NETA/Placebo
treatment
0
Any SAE off treatment 2 (1.0)b
Menometrorrhagia 1 (0.5)
Uterine hemorrhage 1 (0.5)
Breast cancer 1 (0.5)c
Adverse eventsd
Leading to study withdrawale 1 (0.5)
At least one event 120 (57.4)
Headache 34 (16.3)
Nasopharyngitis 14 (6.7)
Abdominal pain (including upper/
lower)
11 (5.3)
Hot flashes 10 (4.8)
Fatigue 9 (4.3)
Nausea 8 (3.8)
Vertigo 8 (3.8)
Breast discomfort/breast pain/breast
tenderness
8 (3.8)
Pelvic pain 8 (3.8)
a All adverse events that occurred during UPA treatment in at least 3% of women overall and
all SAEs are included.
b One woman had two off-treatment SAEs.
c A 46-year-oldwomanwas diagnosedwith a lobular breast cancer 2months after the end of
treatment (T1, grade II).
d Adverse events with onset on or after the first dose of UPA and before the first dose of
NETA/placebo within each treatment course or up to and including 7 days after the last
dose of UPA if NETA/placebo was never started.
e In addition, another adverse event that occurred when a womanwas not receiving UPA led
to study withdrawal.
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SUPPLEMENTAL TABLE 6
Summary of other safety assessments (PEARL III safety set;
n[ 209).
Assessmenta n Result
Serum E2, pg/mL
Screening, median (IQR) 205 120.0 (77, 184)
Course 1, median (IQR) 180 55.0 (41, 84)
ACTH, pg/mL
Screening, median (IQR) 196 13.3 (9.3, 19.8)
Course 1, median (IQR) 177 13.2 (9.2, 17.1)
TSH, mIU/L
Screening, median (IQR) 205 1.36 (0.96, 1.96)
Course 1, median (IQR) 181 1.49 (1.00, 2.00)
PRL, ng/mL
Screening, median (IQR) 205 11.4 (8.2, 18.2)
Course 1, median (IQR) 180 7.9 (5.5, 11.7)
Total cholesterol, mmol/L
Screening, median (IQR) 205 5.06 (4.48, 5.60)
Course 1, median (IQR) 180 5.25 (4.71, 5.82)
Second menstrual bleed
post-treatment,
median (IQR)
123 4.89 (4.41, 5.47)
3-Month follow-up,
median (IQR)
56 5.16 (4.44, 5.93)
HDL, mmol/L
Screening, median (IQR) 205 1.61 (1.43, 1.91)
Course 1, median (IQR) 180 1.64 (1.44, 1.89)
Second menstrual bleed
post-treatment,
median (IQR)
123 1.56 (1.31, 1.81)
3-Month follow-up,
median (IQR)
56 1.72 (1.46, 1.92)
LDL, mmol/L
Screening, median (IQR) 203 2.81 (2.40, 3.39)
Course 1, median (IQR) 178 2.97 (2.55, 3.54)
Second menstrual bleed
post-treatment,
median (IQR)
121 2.72 (2.30, 3.07)
3-Month follow-up,
median (IQR)
56 2.73 (2.19, 3.53)
Endometrial thickness, mm
Screening, mean  SD 202 8.7  3.7
%4 mm, n (%) 14 (6.9)
>4 to%16 mm, n (%) 185 (91.6)
>16 mm, n (%) 3 (1.5)
Course 1, mean  SD 198 9.2  4.6
%4 mm, n (%) 23 (11.6)
>4 to%16 mm, n (%) 157 (79.3)
>16 mm, n (%) 18 (9.1)
2 Weeks after first
menstrual bleed post-
treatment, mean  SD
181 8.9  4.1
%4 mm, n (%) 19 (10.5)
>4 to%16 mm, n (%) 150 (82.9)
>16 mm, n (%) 12 (6.6)
3-Month follow-up,
mean  SD
48 7.6  3.4
%4 mm, n (%) 9 (18.8)
>4 to%16 mm, n (%) 39 (81.3)
>16 mm, n (%) 0
Systolic blood pressure, mmHg
Baseline, mean  SD 209 121.4  13.8
End of week 4, mean SD 207 119.7  13.1
End of week 8, mean SD 203 119.7  13.7
Course 1, mean  SD 202 120.2  13.7
2 Weeks after first
menstrual bleed post-
treatment, mean  SD
191 121.9  12.3
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Assessmenta n Result
Second menstrual bleed
post-treatment,
mean  SD
132 119.8  13.2
3-Month follow-up,
mean  SD
57 120.4  13.6
Diastolic blood pressure, mmHg
Baseline, mean  SD 209 74.4  9.8
End of week 4, mean SD 207 73.4  9.9
End of week 8, mean SD 203 74.0  10.0
Course 1, mean  SD 202 74.2  9.9
2 Weeks after first
menstrual bleed post-
treatment, mean  SD
191 74.9  9.5
Second menstrual bleed
post-treatment,
mean  SD
132 73.6  9.4
3-Month follow-up,
mean  SD
57 74.5  10.8
Pulse rate, bpm
Baseline, mean  SD 209 73.9  10.7
End of week 4, mean SD 207 72.6  9.3
End of week 8, mean SD 203 72.7  9.3
Course 1, mean  SD 201 72.1  9.4
2 Weeks after first
menstrual bleed post-
treatment, mean  SD
191 72.8  9.5
Second menstrual bleed
post-treatment,
mean  SD
132 72.4  10.4
3-Month follow-up,
mean  SD
56 72.2  10.8
Weight, kg
Baseline, mean  SD 209 69.0  12.8
Course 1, mean  SD 202 68.5  12.8
Second menstrual bleed
post-treatment,
mean  SD
132 68.2  13.2
3-Month follow-up,
mean  SD
58 70.2  11.7
Note: n ¼ Number of women with nonmissing observations.
a Course 1 data were collected at the end of UPA treatment. Second menstrual bleed post-
treatment data were collected for those entering the extension; 3-month follow-up data
were collected for those not entering the extension.
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SUPPLEMENTAL TABLE 7
Summary of pathologist consensus of nonphysiological histological
features in the endometrium.
Total
UPA then
Placebo
UPA then
NETA
PEARL III n ¼ 209 n ¼ 103 n ¼ 98
Screening n ¼ 171 n ¼ 85 n ¼ 80
No. of women (%) 18 (10.5) 7 (8.2) 11 (13.8)
2 Weeks after first menstrual
bleed post-treatment
n ¼ 176 n ¼ 92 n ¼ 84
No. of women (%) 45 (25.6) 26 (28.3) 19 (22.6)
PEARL III extension n ¼ 132 n ¼ 69 n ¼ 63
Screening n ¼ 105 n ¼ 56 n ¼ 49
No. of women (%) 11 (10.5) 4 (7.1) 7 (14.3)
2 Weeks after first menstrual
bleed post-treatment
course 1
n ¼ 122 n ¼ 65 n ¼ 57
No. of women (%) 35 (28.7) 20 (30.8) 15 (26.3)
2 Weeks after first menstrual
bleed post-treatment
course 4
n ¼ 87 n ¼ 47 n ¼ 40
No. of women (%) 22 (25.3)a 11 (23.4) 11 (27.5)
Note: n ¼ Number of women with nonmissing observations.
a Of the 22 women diagnosed with a consensus of nonphysiological histological features
2 weeks after first menstrual bleed post-treatment course 4, 15 (7 placebo, 8 NETA) women
had biopsies at 3-month follow-up. Of these, three (1 placebo and 2 NETA) women were
diagnosed with nonphysiological histological features at this follow-up visit.
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SUPPLEMENTAL TABLE 8
Women in amenorrhea at the end of each treatment course by total
volume of a reductionR25% of the three largest fibroids.
Treatment course
Fibroid volume
reductionR25%a Total
Amenorrhea,
n (%)
Course 1 Yes 101 82 (81.2)
No 29 22 (75.9)
Totalb 130 104 (80.0)
Course 2 Yes 95 88 (92.6)
No 24 19 (79.2)
Totalb 119 107 (89.9)
Course 3 Yes 83 74 (89.2)
No 23 21 (91.3)
Totalb 106 95 (89.6)
Course 4 Yes 79 75 (94.9)
No 17 14 (82.4)
Totalb 96 89 (92.7)
a Fibroid volume reduction assessed using total volume of the three largest fibroids assessed
during the screening period before the first treatment course. The same three fibroids iden-
tified at screening were followed throughout the study. Course 1 and 4 data were collected
at the end of UPA treatment; course 2 and 3 data were collected after first menstrual bleed
after UPA treatment and subsequent NETA/placebo treatment.
b Overall totals for each treatment course are the number of women receiving UPA in each
treatment course who did not have surgery performed during or before the end of each
treatment course and who have a nonmissing amenorrhea assessment and nonmissing
fibroid volume reduction assessment for the treatment course in question.
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SUPPLEMENTAL TABLE 9
Summary of other safety assessments (PEARL III extension safety
set; n[ 132)
Assessmenta n Result
Serum E2, pg/mL
Screening, median (IQR) 131 120.0 (76.0, 185.0)
Course 1, median (IQR) 112 54.0 (38.5, 81.0)
Course 2, median (IQR) 119 129.0 (62.0, 194.0)
Course 4, median (IQR) 95 43.0 (27.0, 61.0)
3-Month follow-up,
median (IQR)
96 96.5 (66.5, 173.0)
ACTH, pg/mL
Screening, median (IQR) 126 13.0 (9.3, 19.3)
Course 1, median (IQR) 117 12.7 (9.7, 16.9)
Course 2, median (IQR) 103 12.6 (8.3, 17.3)
Course 4, median (IQR) 86 12.5 (8.1, 16.3)
3-Month follow-up,
median (IQR)
89 13.2 (8.9, 20.9)
TSH, mIU/L
Screening, median (IQR) 131 1.31 (0.94, 1.83)
Course 1, median (IQR) 113 1.41 (0.93, 2.00)
Course 2, median (IQR) 119 1.35 (0.92, 1.88)
Course 4, median (IQR) 95 1.39 (0.84, 2.16)
3-Month follow-up,
median (IQR)
96 1.33 (0.90, 1.85)
PRL, ng/mL
Screening, median (IQR) 131 11.3 (8.9, 18.5)
Course 1, median (IQR) 112 7.55 (5.45, 11.35)
Course 2, median (IQR) 118 8.85 (6.30, 12.90)
Course 4, median (IQR) 95 6.90 (5.10, 11.60)
3-Month follow-up,
median (IQR)
96 9.35 (7.35, 15.35)
Total cholesterol, mmol/L
Screening, median (IQR) 131 5.00 (4.50, 5.58)
Course 1, median (IQR) 112 5.25 (4.93, 5.78)
Course 2, median (IQR) 119 4.97 (4.57, 5.49)
Course 4, median (IQR) 94 5.33 (4.93, 5.85)
3-Month follow-up,
median (IQR)
96 5.17 (4.73, 5.69)
HDL, mmol/L
Screening, median (IQR) 131 1.61 (1.43, 1.88)
Course 1, median (IQR) 112 1.65 (1.41, 1.92)
Course 2, median (IQR) 119 1.59 (1.40, 1.90)
Course 4, median (IQR) 94 1.60 (1.40, 1.87)
3-Month follow-up,
median (IQR)
96 1.62 (1.41, 1.92)
LDL, mmol/L
Screening, median (IQR) 129 2.81 (2.40, 3.38)
Course 1, median (IQR) 110 3.01 (2.60, 3.50)
Course 2, median (IQR) 117 2.77 (2.41, 3.26)
Course 4, median (IQR) 94 3.04 (2.58, 3.62)
3-Month follow-up,
median (IQR)
96 2.95 (2.52, 3.56)
Endometrial thickness, mm
Screening, mean  SD 129 9.3  4.0
%4 mm, n (%) 7 (5.4)
>4 to%16 mm, n (%) 119 (92.2)
>16 mm, n (%) 3 (2.3)
Course 1, mean  SD 130 9.4  4.5
%4 mm, n (%) 13 (10.0)
>4 to%16 mm, n (%) 107 (82.3)
>16 mm, n (%) 10 (7.7)
Course 2, mean  SD 120 8.8  3.8
%4 mm, n (%) 15 (12.5)
>4 to%16 mm, n (%) 101 (84.2)
>16 mm, n (%) 4 (3.3)
Course 3, mean  SD 107 8.0  3.4
%4 mm, n (%) 15 (14.0)
>4 to%16 mm, n (%) 91 (85.0)
>16 mm, n (%) 1 (0.9)
Donnez. Long-term treatment of uterine fibroids. Fertil Steril 2014.
SUPPLEMENTAL TABLE 9
Continued.
Assessmenta n Result
Course 4, mean  SD 95 7.5  3.4
%4 mm, n (%) 17 (17.9)
>4 to%16 mm, n (%) 77 (81.1)
>16 mm, n (%) 1 (1.1)
3-Month follow-up,
mean  SD
97 8.9  3.2
%4 mm, n (%) 6 (6.2)
>4 to%16 mm, n (%) 89 (91.8)
>16 mm, n (%) 2 (2.1)
Systolic blood pressure, mmHg
Baseline, mean  SD 132 122.2  14.1
Course 1, mean  SD 132 120.5  13.6
Course 2, mean  SD 121 120.4  13.7
Course 3, mean  SD 109 120.3  11.4
Course 4, mean  SD 96 120.7  13.3
3-Month follow-up,
mean  SD
99 119.5  11.0
Diastolic blood pressure, mmHg
Baseline, mean  SD 132 74.2  9.3
Course 1, mean  SD 132 74.4  9.7
Course 2, mean  SD 121 74.7  10.3
Course 3, mean  SD 109 73.6  8.8
Course 4, mean  SD 96 74.4  8.1
3-Month follow-up,
mean  SD
99 73.5  9.2
Pulse rate, bpm
Baseline, mean  SD 132 73.8  10.7
Course 1, mean  SD 132 72.5  9.5
Course 2, mean  SD 121 73.8  10.5
Course 3, mean  SD 109 73.3  9.5
Course 4, mean  SD 96 72.2  8.7
3-Month follow-up,
mean  SD
99 72.9  9.5
Weight, kg
Baseline, mean  SD 132 68.7  13.6
Course 1, mean  SD 132 67.8  13.3
Course 2, mean  SD 121 67.3  12.6
Course 3, mean  SD 109 67.5  12.7
Course 4, mean  SD 96 67.4  12.6
3-Month follow-up,
mean  SD
99 67.8  13.3
Note: n ¼ Number of women with nonmissing observations.
a Course 1 and 4 data were collected at the end of UPA treatment; course 2 and 3 data were
collected after first menstrual bleed after UPA treatment and subsequent NETA/placebo
treatment.
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